α-Synuclein and the lewy body disorders

Current Opinion in Neurology

Volumn 14, Issue 4, 2001, Pages 423-432

  Dickson, Dennis W ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

ADAPTATION; ALZHEIMER DISEASE; AUTONOMIC DYSFUNCTION; CELL INCLUSION; CONFORMATIONAL TRANSITION; DEGENERATIVE DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; LEWY BODY; MOLECULAR GENETICS; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN PROCESSING; REVIEW;

EID: 84940364788     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200108000-00001     Document Type: Review

References (85)

1. Mutation in the α-synuclein gene identified in families with Parkinson's disease
2. Ala30Pro mutation in the gene encoding K-synuclein in Parkinson's disease
3. Widespread alterations of alpha-synuclein in multiple system atrophy
4. Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies
5. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy
6. Alpha-synuclein in Lewy body disease and Alzheimer's disease
7. The synuclein family
8. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
9. Alpha-synuclein and Parkinson's disease
10. The precursor protein of non-Aβ component of Alzheimer's disease amyloid (NACP) is a presynaptic protein of the central nervous system
11. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid
12. Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein
13. Axonal transport of synucleins is mediated by all rate components
14. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury
15. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly
16. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease
17. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation
18. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
19. Degradation of alpha-synuclein by proteasome
20. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells
21. Protein degradation by the proteasome and its implications in aging
22. Proteasomal function is impaired in substantia nigra in Parkinson's disease
23. Human and mouse α-synuclein gene: Comparative genomic sequence analysis and identification of a novel gene regulatory element
24. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipo-protein E genotype
25. Polymorphism of NACP-Rep1 in Parkinson's disease: An etiologic link with essential tremor?
26. Interaction of human α-synuclein and Parkinson's disease variants with phospholipids
27. α-Synuclein membrane interactions and lipid specificity
28. Parkinson's disease-associated α-synuclein is more fibrillogenic than β- and α-synuclein and cannot cross-seed its homologues
29. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein
30. Synucleins are a novel class of substrates for G protein-coupled receptor kinases
31. α-Synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases
32. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
33. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
34. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies
35. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide
36. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers, implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies
37. Alpha-synuclein promotes mitochondrial deficit and oxidative stress
38. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
39. Expression of mutant α-synuclein causes increased susceptibility of dopamine toxicity
40. Sensitization of neuronal cells to oxidative stress with mutated human α-synuclein
41. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease
42. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
43. Neuropathology in mice expressing human alpha-synuclein
44. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain
45. Lack of nigral pathology in transgenic mice expression human α-synuclein driven by the tyrosine hydroxylase promoter
46. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
47. A Drosophila model of Parkinson's disease
48. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
49. Tau and synuclein and their role in neuropathotogy
50. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology
51. Widespread expression of α-synuclein and τ immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course
52. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders
53. Accumulation of alpha-synuclein/NACP is a cytopathological features common to Lewy body disease and multiple system atrophy
54. Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease
55. Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on dementia with Lewy bodies international workshop
56. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies
57. Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double-blind, placebo-controlled international study
58. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects
59. Regional cerebral blood flow difference between dementia with Lewy bodies and AD
60. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies
61. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease
62. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease
63. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions
64. Alzheimer-Parkinson disease overlap: Neuropathology
65. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
66. Activated microglial cells and complement factors are unrelated to cortical Lewy bodies
67. Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies
68. Activated microglia in dementia with Lewy bodies
69. Diffuse Lewy body disease: Light and electron microscopic immunocytochemistry of senile plaques
70. Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: Comparison with non-demented cases and Alzheimer's disease
71. Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease
72. Pathogenesis of senile plaques
73. Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry
74. Alzheimer's disease with amygdaloid Lewy bodies: A form of Lewy body disease distinct from AD and diffuse Lewy body disease
75. α-Synuclein-positive structures in cases of sporadic Alzheimer's disease: Morphology and its relationship to tau aggregation
76. Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease
77. Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam
78. Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease
79. Neurodegenerative disease: A different view of diagnosis
80. Pure autonomic failure in association with human α-synucleinopathy
81. REM sleep behavior disorder and degenerative dementia: An association likely reflecting Lewy body disease
82. Hallucinations, REM sleep, and Parkinson's disease: A medical hypothesis
83. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p
84. Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein
85. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains